Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases.
作者信息
Guo Deyin
机构信息
The Centre for Infection and Immunity Studies, School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
出版信息
Virol Sin. 2020 Jun;35(3):253-255. doi: 10.1007/s12250-020-00204-7. Epub 2020 Feb 11.
Abstract
摘要
相似文献
1
Old Weapon for New Enemy: Drug Repurposing for Treatment of Newly Emerging Viral Diseases.对抗新敌人的旧武器：药物重新利用以治疗新出现的病毒性疾病
Virol Sin. 2020 Jun;35(3):253-255. doi: 10.1007/s12250-020-00204-7. Epub 2020 Feb 11.
2
Drug combination therapy for emerging viral diseases.新兴病毒性疾病的药物联合治疗。
Drug Discov Today. 2021 Oct;26(10):2367-2376. doi: 10.1016/j.drudis.2021.05.008. Epub 2021 May 21.
3
Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics.细胞周期蛋白依赖性激酶作为开发新型抗病毒治疗药物的新兴靶点。
Trends Microbiol. 2021 Sep;29(9):836-848. doi: 10.1016/j.tim.2021.01.014. Epub 2021 Feb 19.
4
New pathogenic viruses and novel antiviral drugs.新型致病病毒和新型抗病毒药物。
Expert Rev Anti Infect Ther. 2011 Feb;9(2):161-3. doi: 10.1586/eri.10.166.
5
Intervention strategies for emerging viruses: use of antivirals.新兴病毒的干预策略：抗病毒药物的使用。
Curr Opin Virol. 2013 Apr;3(2):217-24. doi: 10.1016/j.coviro.2013.03.001. Epub 2013 Apr 4.
6
Repurposing Revisited: Exploring the Role of Metformin for Treatment of COVID-19.重新审视药物用途：探索二甲双胍在治疗新冠肺炎中的作用
Clin Infect Dis. 2024 Aug 16;79(2):292-294. doi: 10.1093/cid/ciae154.
7
Antivirals in the time of COVID-19 - not as easy as it looks!新冠疫情下的抗病毒药物——并非看上去那么简单！
Infect Dis Now. 2021 Feb;51(1):2-6. doi: 10.1016/j.medmal.2020.10.010. Epub 2020 Oct 15.
8
Existing antiviral options against SARS-CoV-2 replication in COVID-19 patients.针对 COVID-19 患者中 SARS-CoV-2 复制的现有抗病毒治疗选择。
Future Microbiol. 2020 Dec;15:1747-1758. doi: 10.2217/fmb-2020-0120. Epub 2021 Jan 6.
9
Emerging viral diseases.新出现的病毒性疾病
Md Med. 2008 Winter;9(1):11, 13-6.
10
Antivirals with common targets against highly pathogenic viruses.针对高致病性病毒具有共同靶点的抗病毒药物。
Cell. 2021 Mar 18;184(6):1604-1620. doi: 10.1016/j.cell.2021.02.013.
引用本文的文献
1
Plant resources for immunonutrients and immunomodulators to combat infectious respiratory viral diseases: a review.用于对抗传染性呼吸道病毒性疾病的免疫营养物和免疫调节剂的植物资源：综述
3 Biotech. 2024 Dec;14(12):302. doi: 10.1007/s13205-024-04143-y. Epub 2024 Nov 16.
2
COVID-19 retreats and world recovers: A silver lining in the dark cloud.新冠疫情消退，世界逐渐复苏：黑暗中的一线曙光。
Health Care Sci. 2023 Aug 8;2(4):264-285. doi: 10.1002/hcs2.57. eCollection 2023 Aug.
3
Polypharmacology guided drug repositioning approach for SARS-CoV2.多靶标药物重定位策略用于治疗 SARS-CoV-2。
PLoS One. 2023 Aug 9;18(8):e0289890. doi: 10.1371/journal.pone.0289890. eCollection 2023.
4
Metallo-antiviral aspirants: .金属抗病毒药物候选物： 。
Eur J Med Chem Rep. 2023 Aug;8:100104. doi: 10.1016/j.ejmcr.2023.100104. Epub 2023 Apr 4.
5
The 21st century disaster: The COVID-19 epidemiology, risk factors and control.21世纪的灾难：新型冠状病毒肺炎的流行病学、危险因素及防控
J King Saud Univ Sci. 2023 Jun;35(4):102603. doi: 10.1016/j.jksus.2023.102603. Epub 2023 Feb 20.
6
The prospects of employing probiotics in combating COVID-19.使用益生菌对抗新冠病毒的前景。
Tzu Chi Med J. 2021 Oct 5;34(2):148-159. doi: 10.4103/tcmj.tcmj_104_21. eCollection 2022 Apr-Jun.
7
Role of medicinal plants in inhibiting SARS-CoV-2 and in the management of post-COVID-19 complications.药用植物在抑制新型冠状病毒以及新冠后并发症管理中的作用。
Phytomedicine. 2022 Apr;98:153930. doi: 10.1016/j.phymed.2022.153930. Epub 2022 Jan 5.
8
Genomic Characterization of SARS-CoV2 from Peshawar Pakistan Using Next-Generation Sequencing.利用下一代测序技术对巴基斯坦白沙瓦的 SARS-CoV-2 进行基因组特征分析。
Curr Microbiol. 2022 Jan 4;79(2):48. doi: 10.1007/s00284-021-02743-y.
9
Computational Studies of Selected Transition Metal Complexes as Potential Drug Candidates against the SARS-CoV-2 Virus.作为抗SARS-CoV-2病毒潜在候选药物的选定过渡金属配合物的计算研究
ChemistrySelect. 2021 Aug 6;6(29):7429-7435. doi: 10.1002/slct.202101852. Epub 2021 Aug 11.
10
Genetic Risk Factors for the Development of COVID-19 Coronavirus Infection.新冠病毒感染发展的遗传风险因素
Russ J Genet. 2021;57(8):878-892. doi: 10.1134/S1022795421080056. Epub 2021 Aug 30.
本文引用的文献
1
Protocol for Prevention and Control of COVID-19 (Edition 6).新型冠状病毒肺炎防控方案（第六版）
China CDC Wkly. 2020 May 8;2(19):321-326. doi: 10.46234/ccdcw2020.082.
2
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.瑞德西韦和氯喹在体外能有效抑制新出现的新型冠状病毒（2019 - 新冠病毒）。
Cell Res. 2020 Mar;30(3):269-271. doi: 10.1038/s41422-020-0282-0. Epub 2020 Feb 4.
3
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.中国武汉地区 2019 年新型冠状病毒感染患者的临床特征。
Lancet. 2020 Feb 15;395(10223):497-506. doi: 10.1016/S0140-6736(20)30183-5. Epub 2020 Jan 24.
4
A Novel Coronavirus from Patients with Pneumonia in China, 2019.2019 年中国肺炎患者中的一种新型冠状病毒。
N Engl J Med. 2020 Feb 20;382(8):727-733. doi: 10.1056/NEJMoa2001017. Epub 2020 Jan 24.
5
Drug repurposing for new, efficient, broad spectrum antivirals.药物重定位用于新型、高效、广谱抗病毒药物。
Virus Res. 2019 Apr 15;264:22-31. doi: 10.1016/j.virusres.2019.02.011. Epub 2019 Feb 19.
6
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses.广谱抗病毒药物GS-5734可抑制流行性冠状病毒和人畜共患冠状病毒。
Sci Transl Med. 2017 Jun 28;9(396). doi: 10.1126/scitranslmed.aal3653.
7
GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses.GS-5734 及其母体核苷类似物可抑制副粘病毒、流感病毒和副流感病毒。
Sci Rep. 2017 Mar 6;7:43395. doi: 10.1038/srep43395.
8
Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys.小分子GS-5734对恒河猴体内埃博拉病毒的治疗效果。
Nature. 2016 Mar 17;531(7594):381-5. doi: 10.1038/nature17180. Epub 2016 Mar 2.
9
Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases.羟氯喹和氯喹在治疗系统性红斑狼疮、类风湿关节炎及相关疾病中的治疗和药理学特性。
Inflammopharmacology. 2015 Oct;23(5):231-69. doi: 10.1007/s10787-015-0239-y. Epub 2015 Aug 6.
10
Assessment of safety of the major antimalarial drugs.主要抗疟药物的安全性评估。
Expert Opin Drug Saf. 2007 Sep;6(5):505-21. doi: 10.1517/14740338.6.5.505.
Zotero 插件